Comparing 11 AI Tools for Medical Device Regulatory Affairs (2026): An Independent Selection Guide

Introduction

AI tools built for medical device regulatory affairs now cover most of the submission lifecycle: classification, predicate research, standards and test planning, eSTAR drafting, global registrations, clinical evaluation, and post-market surveillance. They differ sharply in what they automate, which markets they cover, and how much of the work is done by software versus the vendor's own regulatory staff.

This guide is meant to help you start evaluating your options. It lays out eleven tools side by side using the same four questions, so you can map them to your device, your target markets, your submission workload, and your internal regulatory resources, and build a shortlist that works for you.

One point comes before any comparison: these AI tools are tools. They speed up research and first drafts, but none of them can confirm that a submission is correct, and none can be accountable for it. Trained and experienced regulatory affairs professionals are required to verify every output against primary sources and to make sure the submission describes the device consistently from the first section to the last. The manufacturer remains responsible for every statement in a 510(k), De Novo, technical file, or deficiency response, however it was drafted.

Our regulatory team at Kapstone Medical can help you decide where AI tools fit in your regulatory workflow, and can prepare and review the submissions those tools help draft.

Key Takeaways:

• There is no single "best" regulatory AI tool: The tools fall into five groups: FDA submission builders, regulatory intelligence and predicate research, global regulatory information management (RIM), EU MDR clinical and post-market writing, and software development compliance. Most companies need one or two groups, not all five.
• Market coverage is the first filter: Several tools are FDA-only or FDA-first. If you sell into the EU, Brazil, or other markets, confirm coverage for each market before you shortlist a tool.
• "Software or service" decides what you are buying: Some vendors sell a platform your team runs. Others use AI inside their own consulting or registration services and do not sell the software separately. Several offer both.
• AI tools do not replace regulatory professionals" Public 510(k) summaries are thin on technical detail, and AI tools can misstate product codes, special controls, or standard editions. A trained, experienced regulatory affairs professional must confirm every statement and keep the device narrative consistent across the whole submission.
• Confidentiality terms matter: Before uploading design files, test reports, or client data, confirm where data is stored, whether it trains vendor models, and what the vendor's security certifications cover.
• Kapstone stays independent. We provide an unbiased assessment of which tool fits your workload, and we can prepare and review submissions regardless of which tool you choose.

AI tools do not replace regulatory professionals

Our position is direct: every tool in this guide is a research and drafting aid, not a source of regulatory truth. Each output must be confirmed by a trained, experienced regulatory affairs professional before it is used. Two jobs stay with that professional.

Confirming validity. Check every product code, regulation, special control, guidance document, standard and edition, predicate, and test result against the primary source. AI tools can cite superseded guidance, the wrong edition of a standard, or a predicate that does not support the claimed equivalence, and they present these errors with the same confidence as correct answers. Only someone who knows the regulations and the device can tell the difference.

Keeping the device narrative cohesive. A submission tells one story about one device. The device description, indications for use, substantial equivalence comparison, labeling, risk analysis, biocompatibility and human factors rationale, and test summaries must describe the same device, materials, users, and use environment in the same terms. Tools that draft section by section, or from different source files, can produce sections that each read well but contradict each other. FDA reviewers read the submission as a whole, and inconsistencies between sections can lead to additional information requests and delay.

In practice, this means:

• One accountable regulatory lead owns the full submission, not only individual sections.
• The submission is reviewed end to end before it is sent, in addition to section-by-section checks.
• The team keeps a record of which content was AI-drafted and how each item was verified.

How to use this comparison

We asked the same four questions of every tool:

1. Best fit and honest limits: who the tool serves best, and where it is not the right choice.
2. Regulatory scope and coverage: which markets and pathways it supports (510(k), De Novo, PMA, EU MDR/IVDR, other countries), and which data sources it draws on.
3. Getting started, pricing model, and who does the work: self-serve software, enterprise platform, or vendor-delivered service, and how much in-house regulatory expertise it assumes.
4. How the AI is controlled: how outputs are cited or traced to source, how human review is built in, and what the vendor says about validation and data handling.

Match your own situation to the answers below. A startup scoping its first 510(k) has different needs than a manufacturer maintaining registrations in 30 countries, or a CE-marked company keeping clinical evaluation reports current under EU MDR. One note on scope: vendor feature lists change quickly in this category, and most performance figures are vendor-reported. Treat them as claims to test in a trial, not as benchmarks.

The 11 tools at a glance, in alphabetical order

Basil Systems

Answers based on publicly available resources.

Best fit and limits. A regulatory and product-lifecycle intelligence platform for companies that need predicate strategy, competitive landscapes, and post-market signal detection for the US market. The vendor reports that 4 of the 5 largest global device companies use it. It is a research tool, not a drafting tool, and its enterprise model may be more than a small team or a single project needs.

Regulatory scope and coverage. The MedTech module centralizes 510(k)s, PMAs, and product codes, and maps predicate relationships: the predicate a device cited, sibling devices that cited the same predicate, and later devices that cite it. It also supports post-market surveillance and competitive analysis for clinical evaluation. An independent 2026 comparison describes its coverage as primarily FDA.

Getting started, pricing model, and who does the work. Enterprise SaaS with pricing on request. The platform is designed for use across regulatory, clinical, quality, medical affairs, and commercial teams, so value increases with the number of functions that use it.

How the AI is controlled. The platform provides natural-language full-text search across FDA databases. Its Safety Signaling module, launched in 2025, groups related adverse events by confidence level and links each finding to the original source documents, so reviewers can check every signal against the record.

Return to table

Celegence CAPTIS

Answers based on publicly available resources.

Best fit and limits. Cloud software for CE-marked device and IVD manufacturers that maintain clinical evaluation reports, PSURs, and summaries of safety and performance under EU MDR and IVDR. It is of limited use for FDA submission content.

Regulatory scope and coverage. Built for MDR and IVDR, with a focus on post-market surveillance documentation. It integrates with PubMed and Google Scholar for literature screening, and a master data dictionary keeps device information consistent across reports for the same device family. The vendor describes its report templates as Notified Body approved.

Getting started, pricing model, and who does the work. Manufacturers can use CAPTIS with their own medical writers or with Celegence writers working as an extension of the team. Pricing is not published; the vendor offers demos and trials.

How the AI is controlled. CAPTIS Copilot uses pre-trained large language models refined with reinforcement learning from human feedback. The vendor reports that AI and conventional automation halved PMS writing time for its own team. The company has said it held back an AI risk-mapping feature after a subject-matter expert found its accuracy insufficient.

Return to table

Complizen

Answers based on publicly available resources.

Best fit and limits. An FDA platform for startups, small device teams, and consultants preparing traditional 510(k)s, with particular strength in early classification and predicate scoping. It covers FDA only. Predicate comparisons depend on public 510(k) summaries, which rarely describe design or test details in full.

Regulatory scope and coverage. Draws on FDA classification, 510(k), De Novo, PMA, MAUDE, recall, and eCFR data. It returns device class, product code, applicable special controls with 21 CFR citations, relevant guidance, and recognized consensus standards. Predicate research produces similarity-scored shortlists and comparison tables for the substantial equivalence section, plus De Novo and PMA precedent searches.

Getting started, pricing model, and who does the work. Free (by application), Starter, Pro, and Enterprise plans for the software. Consulting is sold separately: a monthly advisory package that pairs the platform with senior FDA expert hours, and a done-for-you 510(k) service. The vendor reports a 94% RTA pass rate on submissions built and reviewed on the platform and 340+ hours saved per submission; both figures are vendor-reported.

How the AI is controlled. An agent called Superagent dispatches subagents to research, draft, and cite, and the vendor states its answers are cited to FDA sources. Teams can upload FDA's written Pre-Sub feedback to update the submission plan. Users export the eSTAR themselves or hand it to Complizen consultants for final review.

Return to table

Cruxi

Answers based on publicly available resources.

Best fit and limits. A web platform for small teams and consultants who want individual AI analyses without a subscription. The company is early-stage: its Capterra listing showed no user reviews as of October 2026, and it does not publish security certifications or the qualifications of its expert reviewers. One independent reviewer noted that users override the AI more often on novel technology.

Regulatory scope and coverage. Covers traditional 510(k), De Novo, PMA, and IDE. Sources include FDA regulations, guidance, product codes, standards, MAUDE events, recalls, and historical 510(k)s. Features include AI classification, predicate identification, automated RTA checks, change impact analysis, and an eSTAR editor.

Getting started, pricing model, and who does the work. Capterra lists one-time fees as of October 2026: $1,000 for the full 510(k) workflow; $200 each for predicate, classification, regulatory assessment, and change impact analyses; and $300 for a pathway assessment, with a free trial. Other directories describe a freemium model, so confirm current pricing with the vendor.

How the AI is controlled. The vendor describes a chain of AI agents with optional expert review. Its public materials describe security only in general terms. Ask how outputs are cited, who reviews them, and where uploaded data is stored.

Return to table

Element RegNav

Answers based on publicly available resources.

Best fit and limits. A compliance-planning service from a large testing, inspection, and certification company, for device teams before or around design freeze. RegNav Premium delivers a compliance plan in under two weeks; RegNav Verify gives an expert-checked review of an existing standards list to find gaps before submission. It produces a plan, not submission content. Element also sells the downstream testing, which buyers should weigh when reviewing the recommended test scope.

Regulatory scope and coverage. Supports Class I, II, and III devices on the 510(k), De Novo, and PMA pathways. The plan sets out the FDA pathway, regulations, product codes, and applicable standards, with a summary of the testing requirements under each standard. At launch it covered FDA only; Element announced plans to add EU MDR and IVDR. Confirm current coverage.

Getting started, pricing model, and who does the work. Sold as tiered services (Premium and Verify). Pricing is not published. Element's regulatory and standards staff take part in each plan.

How the AI is controlled. Proprietary AI is combined with expert review. Element states the expert team includes former notified body regulatory professionals.

Return to table

Ketryx

Answers based on publicly available resources.

Best fit and limits. A compliance platform for software as a medical device and software-intensive devices, built for engineering teams working in Jira, GitHub, GitLab, and Polarion. It automates design documentation and traceability. It does not address regulatory strategy, predicate selection, or submission narratives.

Regulatory scope and coverage. Supports FDA, EU MDR, and ISO documentation, including traceability between requirements, risks, and tests, and software bills of materials. The vendor reports that products built on Ketryx accounted for 2 to 3% of FDA AI/ML software authorizations in 2023.

Getting started, pricing model, and who does the work. The platform sits on top of existing development tools rather than replacing them. A free tier is available to companies that have raised under $2 million; larger companies buy enterprise licenses. The vendor reports use by three of the top five device manufacturers.

How the AI is controlled. Ketryx markets its agents, such as Requirement Conflict Detection, as validated for safety-critical work. The agents flag gaps and propose missing trace links; the vendor states humans stay in the loop for safety-critical decisions.

Return to table

Panacea

Answers based on publicly available resources.

Best fit and limits. An AI-supported FDA consulting firm for drug, biologic, and device companies that want outsourced submission work at fixed milestone fees. It is a service, not a tool your team runs. The company joined Y Combinator in Spring 2026, has a small team, and has a limited public track record.

Regulatory scope and coverage. Lists IND, NDA, BLA, orphan drug, Pre-Sub, 510(k), De Novo, PMA, IDE, and Breakthrough Device designation work.

Getting started, pricing model, and who does the work. Fixed, outcome-based pricing, with payment due when each agreed milestone is complete. Panacea states it hires former FDA staff to perform the work.

How the AI is controlled. The company states its AI handles database searches, literature review, guidance review, and drafting, with consultants reviewing the output. It publishes no technical detail about its platform. Its claim that AI automates 90% of the work is unsupported in public materials.

Return to table

Pure Global AI Builder

Answers based on publicly available resources.

Best fit and limits. Built for companies with an FDA clearance or CE mark that want to register in Brazil. It is not sold as standalone software; it runs inside Pure Global's own registration services. It is currently live only for Brazilian ANVISA notifications and registrations, with Mexico and Southeast Asia announced next.

Regulatory scope and coverage. Extracts data from existing home-market submissions, runs a gap analysis against target-country requirements, flags missing information, and drafts submission files for several markets in parallel from one set of source documents.

Getting started, pricing model, and who does the work. A flat annual fee per device covers dossier compilation, submission, in-country representation, and post-market support. In a pilot of 27 Brazil projects, the vendor reports document assembly fell from 25 to 30 business days to 5 to 8.

How the AI is controlled. Local regulatory specialists in nearly 20 offices maintain the country templates and rule sets, and experts review drafts before submission.

Return to table

RegDesk

Answers based on publicly available resources.

Best fit and limits. An AI-enabled regulatory information management platform for device and IVD companies selling into many markets. An independent 2026 comparison names mid-size companies of 50 to 500 employees with global ambitions as its best fit. It is not built for drafting FDA submission narratives such as eSTAR sections.

Regulatory scope and coverage. Its AI Application Builder generates country-specific submission forms and compliance checklists. Other modules cover regulatory intelligence, change assessment, standards management, distributor collaboration, claims management, and EUDAMED.

Getting started, pricing model, and who does the work. Enterprise software with pricing on request. Implementation involves loading products, registrations, and documents, so plan internal time for set-up.

How the AI is controlled. The platform monitors global regulatory updates and alerts teams to relevant changes, and drafts forms from stored product data. Ask the vendor how generated forms are traced to source requirements and reviewed before filing.

Return to table

Rimsys

Answers based on publicly available resources.

Best fit and limits. A regulatory information management platform for manufacturers with products registered in many countries. The vendor states it supports 6 of the top 12 global device manufacturers, and G2 lists it as a leader in the RIM category. It is a system of record and execution, not a drafting tool, and is more than a small team or single-product company typically needs.

Regulatory scope and coverage. Covers registrations, submissions, UDI (including machine-to-machine transmission to EUDAMED), essential principles, standards management, and regulatory intelligence. A Spring 2026 release added a "Regulatory Execution Engine," and a newer Market Access product assesses entry into a market before resources are committed.

Getting started, pricing model, and who does the work. Enterprise software with pricing on request. Rimsys announced a strategic alliance with KPMG for digital transformation projects, which suggests larger deployments.

How the AI is controlled. Rimsys AI, launched in September 2025, embeds agents into regulatory workflows; the vendor describes them as secure and explainable. Its intelligence module generates impact assessments with an "impacted" or "not impacted" recommendation that a user then evaluates and accepts or overrides.

Return to table

Tento+

Answers based on publicly available resources.

Best fit and limits. A design-control platform for early-stage device innovators who need help identifying applicable standards and requirements. Most public information dates from its 2023 generative AI launch. We could not confirm its current scope, markets, or pricing, so verify these with the vendor.

Regulatory scope and coverage. Users enter a short device description, and the tool generates applicable design standards, automated checklists, design requirements, and test plan suggestions. The company announced a clinical module for safety and effectiveness endpoints and usability protocols.

Getting started, pricing model, and who does the work. Sold as software, with demos on request. In a 2023 trial of 5 projects, the vendor estimated 236 hours saved per submission.

How the AI is controlled. An AI assistant called GeMA generates guidance and drafts. The vendor states the model was tuned with expert input and tested on hundreds of devices; no independent validation is published.

Return to table

Where Kapstone fits

Kapstone's role is to give you an independent view of where AI tools fit in your regulatory work, based on your device, your stage, your target markets, and your team, so you can make an informed decision.

We can help in several situations, whichever tool you use or whether you use one at all:

• Classification and pathway assessments. We confirm product code, device class, and pathway, and check AI-generated classifications against FDA databases and guidance. See Regulatory Strategy for more.
• Predicate and standards strategy. We select and justify predicates and build the standards and test plan, including biocompatibility and human factors scope. See Regulatory Strategy for more.
• Submission preparation and review. We prepare 510(k) and De Novo submissions, or review AI-drafted eSTAR sections before they go to FDA. See Regulatory Submission for more.
• Responses to FDA requests. We draft technical responses to Additional Information letters and deficiencies, including biocompatibility and human factors deficiencies. See Human Factors Engineering for more.

Our Recommendation

Start with the bottleneck, not the tool. If FDA submission drafting is the constraint, trial Complizen and Cruxi side by side on a past 510(k) with a known outcome. If predicate and adverse-event research is the constraint, evaluate Basil Systems. Consider RegDesk, Rimsys, or Pure Global only when you register in several countries, and CAPTIS only when you maintain EU clinical evaluation reports. Whichever tool you choose, treat it as a research and drafting aid only. A trained, experienced regulatory affairs professional must verify its output and own the submission as a single, consistent account of the device.

Have a shortlist and want a second opinion, or need help preparing or reviewing a submission, whatever tool drafted it? Contact Kapstone for an independent assessment.

Capabilities, coverage, pricing, and performance figures are drawn from public materials as of November 2026, are largely vendor-reported, and should be verified against each vendor's current documentation.

Frequently Asked Questions

Can AI-drafted content go into an FDA submission?

The submitter is responsible for the accuracy of everything in a submission, however it was drafted. Verify each product code, regulation citation, guidance reference, and standard edition against the primary source, and have a qualified reviewer sign off on every section.

Which type of tool fits a first 510(k)?

An FDA submission builder (Complizen, Cruxi) covers classification, predicate scoping, and eSTAR drafting. If you have no regulatory staff, a service model (Panacea, or Complizen's consulting) or an outside regulatory team may suit you better than software alone.

We sell in the US and the EU. Can one tool cover both?

Rarely. The FDA submission builders are FDA-only, and CAPTIS is EU-focused. RIM platforms (RegDesk, Rimsys) span markets but manage registrations rather than drafting technical content. Most dual-market companies combine tools or pair one tool with outside support.

How should we check AI-suggested predicates?

Public 510(k) summaries rarely describe design, materials, or test methods in full, so similarity scores rest on limited data. Confirm each predicate is legally marketed, review its recall and MAUDE history, and compare intended use and technological characteristics yourself before relying on it.

Is it safe to upload confidential design files or test reports?

Ask each vendor where data is stored, whether customer data is used to train models, who can access it, and which security certifications apply. Get the answers in the contract, not only in marketing material.

Do these tools need software validation?

Software that creates or holds quality system records, such as traceability or registration data, must be validated for its intended use under ISO 13485 clause 4.1.6, which FDA's Quality Management System Regulation incorporates by reference. For drafting tools, document how outputs are reviewed and approved under your document control procedures.

How do we run a fair trial?

Run the tool on a past submission where you already know the right answer: the cleared predicate, the applicable standards, and any deficiencies FDA raised. Record what it found, what it missed, and what it got wrong.

Will AI tools replace regulatory staff?

No. They shorten database searches, first drafts, and form filling. Regulatory judgment, predicate justification, test strategy, and FDA interaction still need experienced people, as does the final read-through that confirms the submission describes one device consistently from start to finish.

Sources

• Basil Systems: BusinessWire funding release; Medical Economics, Safety Signaling; DIA exhibitor directory; Today’s Medical Developments
• Celegence CAPTIS: BusinessWire launch release; Bio-IT World; YesPress profile
• Complizen: Platform; Predicate research; Submission builder; Pricing; Regulatory advisory
• Cruxi: Capterra listing; QMED; Product Hunt; AI Indigo review
• Element RegNav: Element announcement; BusinessWire; Element development update; IoT Insider
• Ketryx: AWS Marketplace listing; Ketryx press release; Ketryx company history; R&D World
• Panacea: Y Combinator profile
• Pure Global AI Builder: Pure Global announcement; JustAINews; Manufacturing Chemist
• RegDesk: RegDesk AI in Regulatory Affairs; SourceForge RIM listing
• Rimsys: Rimsys AI announcement; Rimsys capabilities; Rimsys Intelligence; BusinessWire, Spring 2026 release; G2 reviews
• Tento+: Medical Device Network; Medical Plastics News
• Independent comparison: MedDeviceGuide, Regulatory Intelligence Software 2026

Additional Resources

• Regulatory Affairs
• Regulatory Strategy
• Regulatory Submission
• Human Factors Engineering
• Quality Management System